C. Strickland

发表

Stabilization of the autoproteolysis of TNF-alpha converting enzyme (TACE) results in a novel crystal form suitable for structure-based drug design studies.

P. Orth, V. Madison, B. Beyer, 2006, Protein engineering, design & selection : PEDS.

Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

M. Snow, P. Weber, P. Kirschmeier, 2002, Journal of medicinal chemistry.

Crystallization of glycosylated human BACE protease domain expressed in Trichoplusia ni.

Yan-Hui Liu, B. Beyer, P. Reichert, 2004, Biochimica et biophysica acta.

Biochemical and structural studies with prenyl diphosphate analogues provide insights into isoprenoid recognition by protein farnesyl transferase.

M. Distefano, C. Strickland, T. Turek-Etienne, 2003, Biochemistry.

Farnesyl protein transferase: Identification of K164α and Y300β as catalytic residues by mutagenesis and kinetic studies

Zhengliang L. Wu, M. Demma, E. Radisky, 1999 .

Crystallization and preliminary X-ray analysis of the acyl carrier protein synthase (AcpS) from Staphylococcus aureus.

P. Orth, D. Daubaras, B. Beyer, 2004, Acta crystallographica. Section D, Biological crystallography.

Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.

W. R. Bishop, F. G. Njoroge, C. Strickland, 2003, Bioorganic & medicinal chemistry.

Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.

S. Sebti, A. Hamilton, Jiazhi Sun, 2006, Organic & biomolecular chemistry.

Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.

P. Orth, A. McPhail, Yong Zhang, 2011, Journal of medicinal chemistry.

Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase

D. Chakrabarti, M. Gelb, F. Buckner, 2007, Antimicrobial Agents and Chemotherapy.

Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue.

Zhanghua Wu, P. Weber, L. Beese, 1998, Biochemistry.

Kukoamine A and other hydrophobic acylpolyamines: potent and selective inhibitors of Crithidia fasciculata trypanothione reductase.

P. Karplus, B. Ganem, S. Savvides, 1995, The Biochemical journal.

Synthesis, Properties, and Applications of Diazotrifluropropanoyl‐Containing Photoactive Analogs of Farnesyl Diphosphate Containing Modified Linkages for Enhanced Stability

C. Schmidt-Dannert, A. Degraw, J. Ochocki, 2010, Chemical biology & drug design.

Cloning, Heterologous Expression, and Distinct Substrate Specificity of Protein Farnesyltransferase from Trypanosoma brucei *

M. Gelb, F. Buckner, H. Erdjument-Bromage, 2000, The Journal of Biological Chemistry.

Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.

P. Weber, R. Doll, W. Windsor, 1999, Journal of medicinal chemistry.

High-level expression, purification, kinetic characterization and crystallization of protein farnesyltransferase beta-subunit C-terminal mutants.

M. Demma, P. C. Weber, W. Windsor, 1999, Protein engineering.

New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.

P. Kirschmeier, Ming Liu, A. Nomeir, 2014, Bioorganic & Medicinal Chemistry Letters.

Discovery of C-imidazole azaheptapyridine FPT inhibitors.

W. R. Bishop, P. Kirschmeier, R. Doll, 2010, Bioorganic & medicinal chemistry letters.

Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.

W. R. Bishop, A. Nomeir, F. G. Njoroge, 2006, Bioorganic & medicinal chemistry letters.

A photoactive isoprenoid diphosphate analogue containing a stable phosphonate linkage: synthesis and biochemical studies with prenyltransferases.

A. Degraw, M. Distefano, K. Cornish, 2007, Journal of Organic Chemistry.

Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc.

R. Doll, J. Reader, J. Baldwin, 2006, Bioorganic & medicinal chemistry letters.

Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.

W. R. Bishop, P. Kirschmeier, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.

W. R. Bishop, P. Weber, P. Kirschmeier, 2002, Bioorganic & medicinal chemistry letters.

Synthesis of (5,6‐Dihydro‐11H‐benzo[5,6]cyclohepta [1,2‐b]pyridin‐11‐ylidene)‐1‐piperidine‐N‐cyanoguanidine Derivatives (I) as Inhibitors of Ras Farnesyl Protein Transferase.

W. R. Bishop, P. Weber, P. Kirschmeier, 2002 .

Bridgehead Modification of Trihalocycloheptabenzopyridine Lead to a Potent Farnesyl Protein Transferase Inhibitor with Improved Oral Metabolic Stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2005 .

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.

Zhuyan Guo, Frank Bennett, Rong-Sheng Yang, 2007, Journal of medicinal chemistry.

Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action

J. O'neil, G. Scapin, M. Bailly, 2021, Communications biology.

Crystal structure of the catalytic domain of human ADAM33.

Jun Zou, P. Orth, V. Madison, 2004, Journal of molecular biology.

Charge is the major discriminating factor for glutathione reductase versus trypanothione reductase inhibitors.

P. Karplus, B. Ganem, S. Savvides, 1996, Bioorganic & medicinal chemistry.

Biochemical and crystallographic characterization of homologous non-peptidic thrombin inhibitors having alternate binding modes.

P. Weber, C. Kettner, C. Strickland, 1998, Acta crystallographica. Section D, Biological crystallography.

Synthesis of farnesyl diphosphate analogues containing ether-linked photoactive benzophenones and their application in studies of protein prenyltransferases.

M. Distefano, C. Strickland, I. Gaon, 2001, The Journal of organic chemistry.

Synthesis of Farnesyl Diphosphate Analogues Containing Ether‐Linked Photoactive Benzophenones and Their Application in Studies of Protein Prenyltransferases.

M. Distefano, C. Strickland, I. Gaon, 2010 .

Structural optimization of cyclic sulfonamide based novel HIV-1 protease inhibitors to picomolar affinities guided by X-ray crystallographic analysis

P. Orth, S. Carroll, C. Strickland, 2014 .

A surface mutant (G82R) of a human α‐glutathione S‐transferase shows decreased thermal stability and a new mode of molecular association in the crystal

J. Rose, C. Strickland, C. Tu, 1994, Proteins.

Overexpression of Crithidia fasciculata trypanothione reductase and crystallization using a novel geometry.

R. Puchalski, P. Karplus, S. Savvides, 1995, Acta crystallographica. Section D, Biological crystallography.